A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

2015143 citationsJournal Articlebronze Open Access

Authors

Matthew M. Heeney · UCSF Benioff Children's Hospital

Carolyn Hoppe · Longwood University

Miguel R. Abboud · Longwood University

Baba Inusa

Julie Kanter · Longwood University

Bernhards Ogutu · Longwood University

Patricia Brown · Longwood University

Abstract

Among children and adolescents with sickle cell anemia, the rate of vaso-occlusive crisis was not significantly lower among those who received prasugrel than among those who received placebo. There were no significant between-group differences in the safety findings. (Funded by Daiichi Sankyo and Eli Lilly; ClinicalTrials.gov number, NCT01794000.).

Topics & Keywords

Hemoglobinopathies and Related Disorders Iron Metabolism and Disorders Pharmacological Effects and Toxicity Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 374, Issue 7, pp. 625-635

DOI: 10.1056/nejmoa1512021

Field-Weighted Citation Impact: 9.00